Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.

Market Analysis and Insights: Global and United States Pemetrexed Market
This report focuses on global and United States Pemetrexed market.
In 2020, the global Pemetrexed market size was US$ 1723.2 million and it is expected to reach US$ 1869.5 million by the end of 2027, with a CAGR of 0.7% during 2021-2027. In United States the Pemetrexed market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Pemetrexed Scope and Market Size
Pemetrexed market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Pemetrexed market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For United States market, this report focuses on the Pemetrexed market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in United States.

Segment by Type
100mg
500mg

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Eli Lilly
Abbott Laboratories
Cadila Healthcare
Eagle Pharmaceuticals
Stada Arzneimittel